双环铂治疗恶性肿瘤疗效和安全性回顾性分析  

A retrospective analysis of the efficacy and safety of dicycloplatin in the treatment of malignant tumor

作　　者：张爽[1] 陈孟莉[1] 尹红[1] 徐风华[1] ZHANG Shuang;CHEN Mengli;YIN Hong;XU Fenghua(Department of Pharmacy,PLA General Hospital,Beijing 100853,China)

机构地区：[1]解放军总医院药学部,北京100853

出　　处：《药学实践杂志》2020年第2期179-183,共5页Journal of Pharmaceutical Practice

摘　　要：目的观察双环铂治疗恶性肿瘤的近期疗效及不良反应。方法回顾性分析我院自2017年1月至2018年8月使用双环铂治疗恶性肿瘤患者的病例,至少化疗2个周期后评价疗效及不良反应。结果平均化疗4个周期的20例患者中,其中完全缓解(CR)1例,部分缓解(PR)4例,稳定(SD)7例,进展(PD)8例,总有效率25%,疾病控制率60%,生活质量KPS评分较治疗前提高(P<0.05)。化疗期间主要毒副作用,表现为骨髓抑制和胃肠道反应。患者白细胞减少、血小板减少、血红蛋白减少、恶心呕吐、肝功能损伤发生率分别是45%、35%、50%、20%、5%。结论以双环铂为主的化疗方案治疗恶性肿瘤有较好的疗效,不良反应较轻可耐受,值得临床进一步观察和应用。Objective To observe the short-term efficacy and adverse reactions of dicycloplatin in the treatment of malignant tumors. Methods A retrospective analysis was performed in our hospital from January 2017 to August 2018 using dicycloplatin to treat patients with malignant tumors. The efficacy and adverse reactions were evaluated after at least 2 cycles of chemotherapy. Results Among the 20 patients with an average of 4 cycles of chemotherapy, 1 had complete remission(CR), 4 had partial remission(PR), 7 had stable diseases(SD), 8 had progression(PD). The total efficacy was 25%. The control rate was60%. The KPS scores for quality of life was higher than that before treatment(P<0.05). The main adverse effects during chemotherapy were bone marrow suppression, gastro-intestinal reactions. The incidence of leukopenia, thrombocytopenia, reduced hemoglobin, nausea vomiting and liver damage was 45%, 35%, 50%, 20%, and 5%, respectively. Conclusion Dicycloplatin-based chemotherapy has a good curative effect on malignant tumors, and the adverse reactions are mild and tolerable, which deserves further clinical observation and application.

关 键 词：双环铂 恶性肿瘤 临床治疗 有效性评价 副作用 

分 类 号：R979.1[医药卫生—药品]